CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

August 21, 2019 admin Healthcare, Investor Presentations Comments Off on CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

CytoDyn, Inc. (OTC: CYDY)

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Next Super Stock investor conference presentation 8/15/2019




Related Articles

Healthcare

FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

March 31, 2020 admin Healthcare, Newsmakers Comments Off on FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

VANCOUVER, Washington, March 31, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

CytoDyn (OTC: CYDY) Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer

November 13, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer

VANCOUVER, Washington, Nov. 12, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has […]

Healthcare

FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s (OTC: CYDY) 510(k) Application for ProstaGene(TM) Prognostic Test

June 24, 2019 admin Healthcare, Newsmakers Comments Off on FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s (OTC: CYDY) 510(k) Application for ProstaGene(TM) Prognostic Test

VANCOUVER, Washington, June 24, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications today announced that […]